PAIGE SOPER: Open Payments
NPI 1205541588 · JOPLIN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$376 in 21 payments from 11 companies in 2025. Trend: 2023 $244 · 2024 $2,086 · 2025 $376
Food & beverage: $376
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 4 | $62 |
| Alnylam Pharmaceuticals Inc. | 3 | $54 |
| Novo Nordisk Inc | 3 | $48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| Amgen Inc. | 2 | $32 |
| Abbott Laboratories | 1 | $31 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Boston Scientific Corporation | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
Products named: AMVUTTRA, LEQVIO, Wegovy, JARDIANCE, REPATHA, JOT DX, WATCHMAN FLX, OPSYNVI.
Industry payments across MO — which companies pay providers there.
